Vaccination and Immunotherapy for Major Depression

Adv Exp Med Biol. 2021:1305:503-513. doi: 10.1007/978-981-33-6044-0_25.

Abstract

Depression is a very common disease with increasing incidence resulting from complex interactions of genetic, environmental, and immunological processes. To this day, the etiopathogenesis and treatment of depression unfortunately seem to be stuck in the synaptic gap. Despite highly potent antidepressants, the treatment rate cannot reach 100%, the treatment resistant group cannot be eliminated, and relapse cannot be prevented. These problems lead researchers to further and different research to understand and treat psychopathology. Immune dysfunction and neuroinflammation have been one of the main issues that psychiatry has focused on in recent years and helps us to understand depression. Extraneuronal components of all neuropsychiatric disorders, especially depression, have begun to be revealed in detail thanks to a better understanding of the immune system and an increase in experimental and technological possibilities. There is increasing evidence of a causal relationship between the etiopathogenesis of major depression and low-level chronic neuroinflammation. In this article, the role of neuroinflammation in the etiopathogenesis of depression and the possibilities of vaccination and immunotherapy are discussed.

Keywords: Depression; Immunotherapy; Neuroinflammation; Vaccination.

MeSH terms

  • Antidepressive Agents / therapeutic use
  • Depression
  • Depressive Disorder, Major* / drug therapy
  • Humans
  • Immunotherapy
  • Vaccination

Substances

  • Antidepressive Agents